Pay vs Performance Disclosure - USD ($)

12 Months Ended

Dec. 31, 2022

Dec. 31, 2021

Dec. 31, 2020

Pay vs Performance Disclosure [Table]

Required Tabular Disclosure of Pay Versus Performance

The amounts set forth below under the headings “Compensation Actually Paid to PEO” and “Average Compensation Actually Paid to

Non-PEO

NEOs” have been calculated in a manner consistent with Item 402(v) of Regulation

S-K.

Use of the term “compensation actually paid” is required by the SEC’s rules and, as a result of the calculation methodology required by the SEC, such amounts differ from compensation actually received by the individuals and the compensation decisions described in the “Compensation Discussion and Analysis” section of this Proxy Statement.


Year	Summary Compensation Table Total for PEO (1) ($)		Compensation Actually Paid to PEO (1)(2) ($)		Average Summary Compensation Table Total for Non-PEO NEOs (1) ($)		Average Compensation Actually Paid to Non-PEO NEOs (1)(2) ($)		Value of Initial Fixed $100 Investment Based On:				Net Income (millions) ($)		Net Product Revenues (millions) (5) ($)
Year	Summary Compensation Table Total for PEO (1) ($)		Compensation Actually Paid to PEO (1)(2) ($)						Total Stockholder Return (3) ($)		Peer Group Total Stockholder Return (4) ($)		Net Income (millions) ($)		Net Product Revenues (millions) (5) ($)
2022		16,877,545		16,020,538		5,149,608		5,038,751		94		116		182.3		1,401.2
2021		7,530,431		15,297,662		3,510,384		5,612,040		107		129		231.1		1,077.3
2020		2,349,812		18,565,411		1,237,199		5,878,678		118		129		111.8		741.6

(1)

Dr. Morrissey was our PEO for each year presented. The individuals comprising the

non-PEO

NEOs for each year presented are as follows: (i) for 2022, Mr. Senner, Dr. Goodman, Mr. Haley and Mr. Hessekiel; (ii) for 2021, Mr. Senner, Mr. Haley, Mr. Hessekiel, Dr. Peter Lamb and Dr. Gisela M. Schwab; and (iii) for 2020, Dr. Schwab, Mr. Senner, Mr. Hessekiel and Mr. Haley.

(2)

Compensation actually paid reflects the exclusions and inclusions of certain amounts for the PEO and the

Non-PEO

NEOs as set forth below. Equity values are calculated in accordance with FASB ASC Topic 718. Amounts in the “Exclusion of Stock Awards and Options Awards” column are the totals from the “Stock Awards” and “Option Awards” columns set forth in the Summary Compensation Table.


Year	Summary Compensation Table Total for PEO ($)		Exclusion of Stock Awards and Options Awards for PEO ($)			Inclusion of Equity Values for PEO ($)		Compensation Actually Paid to PEO ($)
2022		16,877,545		(14,567,256	)		13,710,249		16,020,538
2021		7,530,431		(5,160,513	)		12,927,744		15,297,662
2020		2,349,812		0			16,215,599		18,565,411

Year	Average Summary Compensation Table Total for Non-PEO NEOs ($)		Average Exclusion of Stock Awards and Options Awards for Non-PEO NEOs ($)			Average Inclusion of Equity Values for Non-PEO NEOs ($)		Average Compensation Actually Paid to Non-PEO NEOs ($)
2022		5,149,608		(4,061,664	)		3,950,807		5,038,751
2021		3,510,384		(2,641,508	)		4,743,164		5,612,040
2020		1,237,199		(190,750	)		4,832,229		5,878,678

The amounts in the “Inclusion of Equity Values” columns in the tables above are derived from the amounts set forth in the following tables:


Year	Year End Fair Value of Equity Awards Granted During Year That Remained Unvested as of Last Day of Year for PEO ($)		Year over Year Change in Fair Value of Outstanding and Unvested Equity Awards Granted in Prior Years for PEO ($)		Fair Value as of Vesting Date of Equity Awards Granted and Vested During Year for PEO ($)		Year over Year Change in Fair Value of Equity Awards Granted in Prior Years that Vested During Year for PEO ($)		Fair Value at Last Day of Prior Year of Equity Awards Forfeited During Year for PEO ($)		Total – Inclusion of Equity Values for PEO ($)
2022		11,008,595		1,591,223		0		1,110,432		0		13,710,249
2021		6,464,669		3,180,756		0		3,282,318		0		12,927,744
2020		0		7,832,719		0		8,382,880		0		16,215,599


Year	Average Year End Fair Value of Equity Awards Granted During Year That Remained Unvested as of Last Day of Year for Non-PEO NEOs ($)		Average Year over Year Change in Fair Value of Outstanding and Unvested Equity Awards Granted in Prior Years for Non-PEO NEOs ($)		Average Fair Value as of Vesting Date of Equity Awards Granted and Vested During Year for Non-PEO NEOs ($)		Average Year over Year Change in Fair Value of Equity Awards Granted in Prior Years that Vested During Year for Non-PEO NEOs ($)			Average Fair Value at Last Day of Prior Year of Equity Awards Forfeited During Year for Non-PEO NEOs ($)		Total – Average Inclusion of Equity Values for Non-PEO NEOs ($)
2022		3,080,814		443,853		123,352		302,788			0		3,950,807
2021		1,324,859		721,634		288,187		2,408,484	(a)		0		4,743,164
2020		175,613		2,259,042		0		2,397,575			0		4,832,229

(a)

Amount includes the addition of the aggregate incremental fair value associated with the modifications of Dr. Schwab’s equity awards in September 2021.

(3)

Cumulative TSR is calculated by dividing the sum of the cumulative amount of dividends for the measurement period, assuming dividend reinvestment, and the difference between our share price at the end and the beginning of the measurement period by our share price at the beginning of the measurement period. The beginning of the measurement period for each year in the table is January 3, 2020.

(4)	The peer group used for this purpose is the Nasdaq Biotechnology Index, which we also utilize in the stock performance graph required by Item 201(e) of Regulation S-K included in our Annual Report for the fiscal year ended December 30, 2022.

(5)

SEC rules require us to designate a “Company-Selected Measure” that in our assessment represents the most important financial performance measure used by us to link the compensation actually paid to our PEO and

non-PEO

NEOs, for the most recently completed fiscal year, to our performance. We have selected Net Product Revenues as this measure for fiscal 2022.

Company Selected Measure Name

Net Product Revenues

Named Executive Officers, Footnote [Text Block]

(1)

Dr. Morrissey was our PEO for each year presented. The individuals comprising the

non-PEO

Peer Group Issuers, Footnote [Text Block]

(4)	The peer group used for this purpose is the Nasdaq Biotechnology Index, which we also utilize in the stock performance graph required by Item 201(e) of Regulation S-K included in our Annual Report for the fiscal year ended December 30, 2022.

PEO Total Compensation Amount

$ 16,877,545

$ 7,530,431

$ 2,349,812

PEO Actually Paid Compensation Amount

$ 16,020,538

15,297,662

18,565,411

Adjustment To PEO Compensation, Footnote [Text Block]

(2)

Compensation actually paid reflects the exclusions and inclusions of certain amounts for the PEO and the

Non-PEO


Year	Summary Compensation Table Total for PEO ($)		Exclusion of Stock Awards and Options Awards for PEO ($)			Inclusion of Equity Values for PEO ($)		Compensation Actually Paid to PEO ($)
2022		16,877,545		(14,567,256	)		13,710,249		16,020,538
2021		7,530,431		(5,160,513	)		12,927,744		15,297,662
2020		2,349,812		0			16,215,599		18,565,411

Year	Average Summary Compensation Table Total for Non-PEO NEOs ($)		Average Exclusion of Stock Awards and Options Awards for Non-PEO NEOs ($)			Average Inclusion of Equity Values for Non-PEO NEOs ($)		Average Compensation Actually Paid to Non-PEO NEOs ($)
2022		5,149,608		(4,061,664	)		3,950,807		5,038,751
2021		3,510,384		(2,641,508	)		4,743,164		5,612,040
2020		1,237,199		(190,750	)		4,832,229		5,878,678

The amounts in the “Inclusion of Equity Values” columns in the tables above are derived from the amounts set forth in the following tables:


Year	Year End Fair Value of Equity Awards Granted During Year That Remained Unvested as of Last Day of Year for PEO ($)		Year over Year Change in Fair Value of Outstanding and Unvested Equity Awards Granted in Prior Years for PEO ($)		Fair Value as of Vesting Date of Equity Awards Granted and Vested During Year for PEO ($)		Year over Year Change in Fair Value of Equity Awards Granted in Prior Years that Vested During Year for PEO ($)		Fair Value at Last Day of Prior Year of Equity Awards Forfeited During Year for PEO ($)		Total – Inclusion of Equity Values for PEO ($)
2022		11,008,595		1,591,223		0		1,110,432		0		13,710,249
2021		6,464,669		3,180,756		0		3,282,318		0		12,927,744
2020		0		7,832,719		0		8,382,880		0		16,215,599


Year	Average Year End Fair Value of Equity Awards Granted During Year That Remained Unvested as of Last Day of Year for Non-PEO NEOs ($)		Average Year over Year Change in Fair Value of Outstanding and Unvested Equity Awards Granted in Prior Years for Non-PEO NEOs ($)		Average Fair Value as of Vesting Date of Equity Awards Granted and Vested During Year for Non-PEO NEOs ($)		Average Year over Year Change in Fair Value of Equity Awards Granted in Prior Years that Vested During Year for Non-PEO NEOs ($)			Average Fair Value at Last Day of Prior Year of Equity Awards Forfeited During Year for Non-PEO NEOs ($)		Total – Average Inclusion of Equity Values for Non-PEO NEOs ($)
2022		3,080,814		443,853		123,352		302,788			0		3,950,807
2021		1,324,859		721,634		288,187		2,408,484	(a)		0		4,743,164
2020		175,613		2,259,042		0		2,397,575			0		4,832,229

(a)

Amount includes the addition of the aggregate incremental fair value associated with the modifications of Dr. Schwab’s equity awards in September 2021.

Non-PEO NEO Average Total Compensation Amount

$ 5,149,608

3,510,384

1,237,199

Non-PEO NEO Average Compensation Actually Paid Amount

$ 5,038,751

5,612,040

5,878,678

Adjustment to Non-PEO NEO Compensation Footnote [Text Block]

(2)

Compensation actually paid reflects the exclusions and inclusions of certain amounts for the PEO and the

Non-PEO


Year	Summary Compensation Table Total for PEO ($)		Exclusion of Stock Awards and Options Awards for PEO ($)			Inclusion of Equity Values for PEO ($)		Compensation Actually Paid to PEO ($)
2022		16,877,545		(14,567,256	)		13,710,249		16,020,538
2021		7,530,431		(5,160,513	)		12,927,744		15,297,662
2020		2,349,812		0			16,215,599		18,565,411

Year	Average Summary Compensation Table Total for Non-PEO NEOs ($)		Average Exclusion of Stock Awards and Options Awards for Non-PEO NEOs ($)			Average Inclusion of Equity Values for Non-PEO NEOs ($)		Average Compensation Actually Paid to Non-PEO NEOs ($)
2022		5,149,608		(4,061,664	)		3,950,807		5,038,751
2021		3,510,384		(2,641,508	)		4,743,164		5,612,040
2020		1,237,199		(190,750	)		4,832,229		5,878,678

The amounts in the “Inclusion of Equity Values” columns in the tables above are derived from the amounts set forth in the following tables:


Year	Year End Fair Value of Equity Awards Granted During Year That Remained Unvested as of Last Day of Year for PEO ($)		Year over Year Change in Fair Value of Outstanding and Unvested Equity Awards Granted in Prior Years for PEO ($)		Fair Value as of Vesting Date of Equity Awards Granted and Vested During Year for PEO ($)		Year over Year Change in Fair Value of Equity Awards Granted in Prior Years that Vested During Year for PEO ($)		Fair Value at Last Day of Prior Year of Equity Awards Forfeited During Year for PEO ($)		Total – Inclusion of Equity Values for PEO ($)
2022		11,008,595		1,591,223		0		1,110,432		0		13,710,249
2021		6,464,669		3,180,756		0		3,282,318		0		12,927,744
2020		0		7,832,719		0		8,382,880		0		16,215,599


Year	Average Year End Fair Value of Equity Awards Granted During Year That Remained Unvested as of Last Day of Year for Non-PEO NEOs ($)		Average Year over Year Change in Fair Value of Outstanding and Unvested Equity Awards Granted in Prior Years for Non-PEO NEOs ($)		Average Fair Value as of Vesting Date of Equity Awards Granted and Vested During Year for Non-PEO NEOs ($)		Average Year over Year Change in Fair Value of Equity Awards Granted in Prior Years that Vested During Year for Non-PEO NEOs ($)			Average Fair Value at Last Day of Prior Year of Equity Awards Forfeited During Year for Non-PEO NEOs ($)		Total – Average Inclusion of Equity Values for Non-PEO NEOs ($)
2022		3,080,814		443,853		123,352		302,788			0		3,950,807
2021		1,324,859		721,634		288,187		2,408,484	(a)		0		4,743,164
2020		175,613		2,259,042		0		2,397,575			0		4,832,229

(a)

Amount includes the addition of the aggregate incremental fair value associated with the modifications of Dr. Schwab’s equity awards in September 2021.

(3)

(4)	The peer group used for this purpose is the Nasdaq Biotechnology Index, which we also utilize in the stock performance graph required by Item 201(e) of Regulation S-K included in our Annual Report for the fiscal year ended December 30, 2022.

(5)

non-PEO

NEOs, for the most recently completed fiscal year, to our performance. We have selected Net Product Revenues as this measure for fiscal 2022.

Compensation Actually Paid vs. Total Shareholder Return [Text Block]

Compensation Actually Paid Compared to TSR

Compensation Actually Paid vs. Net Income [Text Block]

Compensation Actually Paid compared to Net Income

Compensation Actually Paid vs. Company Selected Measure [Text Block]

Compensation Actually Paid compared to Net Product Revenues

Total Shareholder Return Vs Peer Group [Text Block]

Compensation Actually Paid Compared to TSR

Tabular List [Table Text Block]

Required Tabular Disclosure of Most Important Performance Measures

The most important performance measures used to link compensation actually paid to our NEOs for 2022 to Company performance are set forth below. For further information regarding these performance metrics and their function in our executive compensation program, please refer to the “Compensation Discussion and Analysis” section of this Proxy Statement.

Relative TSR

Net Product Revenues

Total Shareholder Return Amount

$ 94

107

118

Peer Group Total Shareholder Return Amount

116

129

Net Income (Loss)

$ 182,300,000

$ 231,100,000